Celecoxib as Adjuvant Biologic Therapy in Patients With Early Stage Head and Neck and Lung Cancer

Trial Profile

Celecoxib as Adjuvant Biologic Therapy in Patients With Early Stage Head and Neck and Lung Cancer

Discontinued
Phase of Trial: Phase II

Latest Information Update: 05 Dec 2012

At a glance

  • Drugs Celecoxib (Primary)
  • Indications Head and neck cancer; Non-small cell lung cancer
  • Focus Biomarker; Therapeutic Use
  • Most Recent Events

    • 26 Mar 2010 Actual patient number (1) added as reported by ClinicalTrials.gov.
    • 26 Mar 2010 Status changed from active, no longer recruiting to discontinued as reported by ClinicalTrials.gov.
    • 12 Mar 2010 Planned end date (1 Sep 2008) added as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top